GlassScriptPhysician profile
Wendy Chen
NPI 1659317469
$1,964.11
in general payments reported to CMS, 2019-2025
28 companies · $685 in 2025
The $685 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.14 · 2020: $38.58 · 2021: $13.34 · 2024: $1,216 · 2025: $685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,901.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,901.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $344.07 | 2024-2025 | Tecvayli, Talvey, Darzalex |
| Astrazeneca Pharmaceuticals LP | $251.34 | 2024-2025 | Imfinzi, Enhertu, Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $150.96 | 2024-2025 | |
| Pfizer INC. | $142.16 | 2020-2024 | |
| Daiichi Sankyo INC. | $114.96 | 2024-2025 | Enhertu, Vanflyta |
| Genmab U.S., INC. | $92.88 | 2024 | Epkinly |
| Takeda Pharmaceuticals U.S.A., INC. | $79.24 | 2024-2025 | Fruzaqla, Ninlaro, Alunbrig |
| Pharmaessentia USA Corporation | $78.23 | 2024-2025 | Besremi |
| Genzyme Corporation | $66.66 | 2024 | |
| Karyopharm Therapeutics INC. | $66.63 | 2024-2025 | Xpovio |
| Abbvie INC. | $65.86 | 2025 | |
| Alexion Pharmaceuticals, INC. | $62.58 | 2024-2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $53.34 | 2025 | |
| Exelixis INC. | $50.71 | 2025 | Cabometyx |
| Sobi, INC | $45.91 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $44.16 | 2024 | Ojjaara |
| Gilead Sciences, INC. | $40.08 | 2025 | Trodelvy |
| Astellas Pharma US INC | $39.86 | 2025 | Vyloy |
| Octapharma USA, INC. | $22.98 | 2024 | Octagam Immune Globulin (Human) |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.31 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $21.16 | 2024 | Truxima |
| Beigene USA, INC. | $20.54 | 2024 | Brukinsa |
| Stemline Therapeutics INC. | $17.21 | 2024 | Orserdu |
| Adaptive Biotechnologies Corporation | $16.30 | 2024 | Clonoseq |
| Incyte Corporation | $14.85 | 2024 | Jakafi |
| Aimmune Therapeutics, INC. | $14.26 | 2025 | Zenpep |
| Celgene Corporation | $13.73 | 2025 | Reblozyl |
| Baxter Healthcare | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendy Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.